Efficacy of Omadacycline Versus Moxifloxacin in the Treatment of Community-Acquired Bacterial Pneumonia by Disease Severity: Results From the OPTIC Study.

Ramirez, Julio; Deck, Daniel H; Eckburg, Paul B; Curran, Marla; Das, Anita F; Kirsch, Courtney; Manley, Amy; Tzanis, Evan; McGovern, Paul C

Ramirez, Julio; Deck, Daniel H; Eckburg, Paul B; Curran, Marla; Das, Anita F; Kirsch, Courtney; Manley, Amy; Tzanis, Evan; McGovern, Paul C.

Affiliation

Ramirez J; Division of Infectious Diseases, Department of Medicine, University of Louisville, Louisville, Kentucky, USA.
Deck DH; Paratek Pharmaceuticals, Inc., King of Prussia, Pennsylvania, USA.
Eckburg PB; Paratek Pharmaceuticals, Inc., King of Prussia, Pennsylvania, USA.
Curran M; Paratek Pharmaceuticals, Inc., King of Prussia, Pennsylvania, USA.
Das AF; AD Stats Consulting, Guerneville, California, USA.
Kirsch C; Paratek Pharmaceuticals, Inc., King of Prussia, Pennsylvania, USA.
Manley A; Paratek Pharmaceuticals, Inc., King of Prussia, Pennsylvania, USA.
Tzanis E; Paratek Pharmaceuticals, Inc., King of Prussia, Pennsylvania, USA.
McGovern PC; Paratek Pharmaceuticals, Inc., King of Prussia, Pennsylvania, USA.

Open Forum Infect Dis ; 8(6): ofab135, 2021 Jun.

Article in En | MEDLINE | ID: mdl-34160474

Key words

community-acquired bacterial pneumonia; moxifloxacin; omadacycline; severity

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Clinical_trials Language: En Journal: Open Forum Infect Dis Year: 2021 Document type: Article Affiliation country: Estados Unidos Country of publication: Estados Unidos

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google